Pharmaceutical Company to Pay $20 Million to Settle False Claims Charges
- August 28, 2020
DUSA Pharmaceuticals, Inc., a subsidiary of Sun Pharmaceutical Industries, Inc., has agreed to pay the United States $20.75 million to resolve allegations that it caused physicians to submit false claims to Medicare and the Federal Employee Health Benefit Program by knowingly promoting an administration process for the drug Levulan Kerastick that contradicted the product instructions approved by the Food and Drug Administration (FDA) and was unsupported by sufficient clinical evidence, the Department of Justice announced August 24.
ARTICLE TAGS
You must be logged in to access this content.